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Abstract  34 
Background: Cardiovascular (CV) disease is the leading cause of death in kidney and 35 
simultaneous pancreas-kidney (SPK) transplant recipients. Assessing abdominal aortic 36 
calcification (AAC), using lateral spine x-rays and the Kaupilla 24-point AAC (0-24) score, 37 
may identify transplant recipients at higher CV risk.  38 
Methods: Between the years 2000-2015, 413 kidney and 213 SPK first transplant recipients 39 
were scored for AAC at time of transplant and then followed for CV events (coronary heart, 40 
cerebrovascular or peripheral vascular disease), graft-loss and all-cause mortality.  41 
Results: The mean age was 44 ± 12 years (SD) with 275 (44%) having AAC (26% moderate: 42 
1-7 and 18% high: ≥8). After a median of 65 months (IQR 29-107 months), 46 recipient’s 43 
experienced CV events, 59 died and 80 suffered graft loss. For each point increase in AAC, 44 
the unadjusted hazard ratios (HR) for CV events and mortality were 1.11 (95% CI 1.07-1.15) 45 
and 1.11 (1.08-1.15). These were similar after adjusting for age, gender, smoking, transplant 46 
type, dialysis vintage and diabetes: aHR 1.07 (95% CI 1.02-1.12) and 1.09 (1.04-1.13). For 47 
recipients with high versus no AAC, the unadjusted and fully-adjusted HR for CV events 48 
were 5.90 (2.90-12.02) and 3.51 (1.54-8.00), for deaths 5.39 (3.00-9.68) and 3.38 (1.71-6.70), 49 
and for graft loss 1.30 (0.75-2.28) and 1.94 (1.04-3.27) in age and smoking history-adjusted 50 
analyses.  51 
Conclusion: Kidney and SPK transplant recipients with high AAC have 3-fold higher CV 52 
and mortality risk and poorer graft outcomes than recipients without AAC. AAC scoring may 53 
be useful in assessing and targeted risk-lowering strategies.  54 
 55 
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Introduction 67 
Patients with chronic kidney disease (CKD) have increased atherosclerosis, large-vessel 68 
remodelling or arteriosclerosis[1], a propensity for arterial calcification[2] and substantially 69 
higher risks for cardiovascular (CV) events[3]. Although kidney transplant recipients have 70 
improved survival compared to patients on dialysis, they nevertheless have 3-5 times higher 71 
CV risk than people from the age-matched general population[4,5]. For patients undergoing 72 
simultaneous pancreas-kidney (SPK) transplantation, this risk may be even greater due to the 73 
cumulative vascular burden associated with type 1 diabetes mellitus and end-stage kidney 74 
disease (ESKD)[6]. Age and prior CV events are predictive of outcomes[7], but further 75 
means to stratify risk and to target treatment strategies are poorly understood. 76 
In the general population abdominal aortic calcification (AAC) is commonly present as focal 77 
intimal or atherosclerotic calcifications[8,9] and is associated with increased cardiovascular 78 
(CV) risk[10]. The development and progression of AAC is a dynamic, actively regulated 79 
process, and is commonly described in patients with ESKD [11,12], in whom the process of 80 
vascular calcification is exacerbated by abnormal mineral metabolism and alterations to local 81 
and systemic inhibitors of calcification[13]. By the time patients require kidney or SPK 82 
transplantation, endothelial dysfunction and atherosclerosis is common, with 50-60% having 83 
detectable vascular calcification [6,7,14].  Even after kidney transplantation, calcification of 84 
the thoracic aorta and coronary arteries progresses at median rates of 4 and 11%, respectively, 85 
per year[15]. 86 
AAC can be assessed from lateral spine X-rays that include the abdominal aorta, or from 87 
dual-energy X-ray absorptiometry (DXA) lateral spine images, using the Kauppila AAC-24 88 
point semi-quantitative scale[16]. For this scoring method, the anterior and posterior walls of 89 
the aorta are divided into 4 regions corresponding to the L1-L4 vertebrae (8 segments). Each 90 
segment is scored zero if there is no calcification, 1 for ≤1/3rd of the segment calcified, 2 for 91 
1/3 to ≤2/3rds calcified, and 3 for >2/3rds calcified. Scores for the 8 segments are then added 92 
for a maximum score of 24/24. In a study of 531 patients admitted for kidney  (69%) and 93 
SPK (31%) transplantation[7], AAC was significantly associated with age, dialysis vintage, 94 
smoking, pre-existing vascular disease, and with diabetes for patients undergoing kidney only 95 
transplants[7].   96 
To date, a number of studies have reported associations of AAC to cardiovascular risk and 97 
mortality. These include a retrospective study of 253 patients with 3 years median follow up 98 
[6], a study using dual-energy X-ray absorptiometry for AAC assessment [17], a study of 134 99 
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patients commencing 7 to 9 years after transplantation [18] and a retrospective study of 119 100 
patients, which reported ACC was not predictive of patient survival in multivariable analyses 101 
[19]. To date, no study has reported on the association of AAC with cardiovascular or 102 
mortality outcomes in SPK recipients. 103 
The primary aim of this study was to determine whether AAC scores at the time of kidney or 104 
SPK transplantation were associated with cardiovascular events and all-cause mortality. A 105 
secondary aim was to determine the association of AAC with death-censored kidney and/or 106 
pancreas graft loss. 107 
 108 
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Materials and Methods 133 
The manuscript complies with the STROBE reporting guidelines for observational studies 134 
[20].  135 
Statement of ethics 136 
The study was approved by the Western Sydney Local Health District Human Research 137 
Ethics Committee (LNR/13/WMEAD/64) and complies with the ‘Declaration of Istanbul on 138 
Organ Trafficking and Transplant Tourism’. 139 
Study population  140 
Recruitment of this cohort has been described previously [7]. Briefly, a lateral lumbar spine 141 
X-ray including the abdominal aorta was performed within four weeks of transplantation on 142 
695/900 (77%) consecutive patients admitted to Westmead Hospital, Sydney, for kidney or 143 
SPK transplantation between 2000 and 2015. Patients without a lateral spine X-ray included 144 
those with post-operative complications, those who returned soon after transplantation to 145 
their referring renal unit and those who did not attend their scheduled visit to the clinic. Only 146 
first transplant recipients were included and patients with suspected or proven CV disease 147 
(coronary artery disease, cerebrovascular disease or peripheral vascular disease) and heart 148 
failure were excluded. The final dataset consisted of 623 transplant recipients (Figure 1A).  149 
 150 
Study population demographics and comorbidities  151 
Pre-transplant demographic and clinical data was collected directly from transplant recipients 152 
during their clinic visit within four weeks of transplant, and included body mass index (BMI), 153 
intercurrent illnesses including diabetes (none, type I and type II), information on smoking 154 
status (never, former and current) and pre-transplant medications. Prevalent co-morbidities 155 
and racial background were obtained through data linkage to the Australia and New Zealand 156 
Dialysis and Transplant (ANZDATA) registry. Blood was collected within the 24 hours 157 
preceding transplantation for routine biochemistry, hormonal studies including intact-158 
parathyroid hormone (PTH) and bone turnover markers as described previously[7]. 159 
 160 
Abdominal aortic calcification 24 scores (AAC24) 161 
Lateral spine X-rays (example in Figure 1B) including the abdominal aorta were performed 162 
within 4 weeks of transplantation. AAC was quantified using an established 24 point scoring 163 
scale [16], assigned prospectively by an experienced clinician (GJE, MVD) at the immediate 164 
post-transplant consultation, with high blinded inter-observer consistency (Spearman’s 165 
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rho=0.91, P<0.001), as described previously [7]. Suspected and proven CV disease was an 166 
exclusion criterion for this study.  AAC was examined in three ways; i) semi-continuous 167 
variable on the AAC 24 point scale, ii) present vs. absent and iii) using previously published 168 
cut points from a prior study of kidney transplant recipients of no AAC, moderate AAC 169 
(score 1-7) and high AAC (score 8-24), respectively [6].  170 
 171 
Cardiovascular events and all-cause mortality 172 
The primary endpoints were CV events (coronary artery disease, cerebrovascular disease or 173 
peripheral vascular disease) and/or deaths (events) and all-cause mortality obtained from 174 
ANZDATA. For CV events, patients are classified as ‘yes’, ‘no’ or ‘suspected’. Patients with 175 
‘suspected’ or confirmed CV or a CV-related death after transplantation were deemed to have 176 
an incident CV event. Time to event data was calculated from transplant date to date of first 177 
CV event, date of death or the 31st of December 2015, whichever came first. Death–censored 178 
kidney graft loss, death-censored pancreas graft loss and any death-censored graft loss 179 
(kidney and/or pancreas) was considered a secondary outcome. Data on kidney and pancreas 180 
graft outcomes was obtained from the ANZDATA or the Australian and New Zealand Islet 181 
and Pancreas Transplant Registries and graft failure dates corresponded to dates of graft 182 
removal or return to dialysis (kidney) or the use of insulin more than 0.5 units per kg per day 183 
over a period of 90 consecutive days (pancreas). 184 
. 185 
 186 
Statistical analysis 187 
Baseline data are presented as mean ± SD, median and IQR or number and (%) where 188 
appropriate. The association of the presence of AAC (yes or no) or AAC24 severity (none, 189 
moderate or high) with incident CV events (hospitalization or death) was assessed in 190 
unadjusted and multivariable-adjusted Cox proportional hazards regression analyses. For the 191 
primary analyses for CV events, we treated deaths as censored. For the primary analyses with 192 
all-cause mortality we did not censor for graft loss. As a further analysis we censored at the 193 
time of kidney graft failure (death with a functioning kidney graft outcome, n=44 or death 194 
with any functioning kidney or pancreas graft outcome, n=41). To avoid overfitting models 195 
with low event rates (n=41-60), we performed multivariate Cox proportional hazards 196 
regression analyses adjusted for either age, or age, gender, smoking, transplant type, dialysis 197 
vintage and diabetes. In addition, multivariable models for graft loss included donor factors; 198 
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organ source (deceased or living), age and ischemia time (hours). For secondary outcomes of 199 
kidney graft loss or any graft loss (kidney and/or pancreas) we undertook forward stepwise 200 
Cox regression with age, gender, smoking history, transplant type, dialysis vintage, diabetes, 201 
organ source, donor age, ischemia time and HLA mismatch (0-6, number). The final model 202 
for both kidney and any graft loss (kidney and/or pancreas) included age and smoking 203 
history. We tested for linear trends across AAC categories by using the median AAC24 value 204 
for each category (low = 0, moderate = 3, or high = 11). Additionally, dose-response 205 
relationships between AAC scores and cardiovascular disease events and all-cause mortality 206 
outcomes were examined with restricted cubic splines [21]. Given the high risk of non-CV 207 
death, we performed competing-risks analyses based on Fine and Gray’s proportional sub-208 
distribution hazards model [22]. Cox proportional hazards assumptions were tested with the 209 
Schoenfeld residuals. No violations of the Cox proportional hazards assumptions were 210 
detected. Analyses were undertaken using SPSS Version 22 (2012, Armonk, NY: IBM Corp), 211 
STATA Version 13 (StataCorp LP, College Station, TX) or R (R Foundation for Statistical 212 
Computing, Vienna, Austria).  213 
 214 
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 218 
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Results 228 
Cohort characteristics  229 
An overview of the study recruitment is provided in Figure 1A. The median follow up of 230 
transplant recipients was 65 months (IQR 29-107 months). SPK recipients were younger, had 231 
lower BMI, shorter dialysis vintage and were less ethnically diverse, all P<0.05, (Table 1). 232 
Medication data was available in 440 recipients. The percentage of patients prescribed 233 
calcium-based phosphate binders, calcitriol and cinacalcet prior to transplant was 75.9%, 234 
44.6% and 5.2% respectively. There were no statistically significant differences in the risk of 235 
CV events (7.5% vs. 7.3%, P=0.930) or deaths (10.3% vs. 9.0%, P=0.598) between SPK and 236 
kidney transplant recipients. AAC24 scores were skewed in both the kidney transplant and 237 
the SPK transplant recipients.  238 
 239 
Presence of AAC and cardiovascular events and all-cause mortality 240 
Of 623 kidney and SPK transplant recipients, 275 (44%) had detectable and 348 (66%) had 241 
no detectable AAC at time of transplantation. For transplant recipients with no detectable 242 
AAC, 3.7% had a CV event while 5.5% died of any cause. For transplant recipients with 243 
detectable AAC, 12.0% had a CV event while 14.5% died of any cause. Kaplan Meier 244 
survival plots for time to CV events and to death are presented in Figure 2 a & b. When 245 
investigating kidney and SPK transplant recipients separately, similar findings were seen 246 
(Figure 3 a-d). No interaction was observed between AAC24 scores and transplant type for 247 
CV events (P=0.578) or all-cause mortality (P=0.153). Transplant recipient groups were 248 
therefore combined for the main analyses. 249 
 250 
AAC scores as continuous measures 251 
In unadjusted analyses for each 1 point increase in AAC24 score there was a 11% increase in 252 
risk of CV events (HR 1.11 95%CI [1.07-1.15], P<0.001 and all-cause mortality HR 1.11 253 
95%CI [1.08-1.15], P<0.001). For each 1 point increase in AAC24 score there was a 7-8% 254 
increase in age and multivariable-adjusted risk of CV events (age-adjusted HR 1.08 95%CI 255 
[1.04-1.13], P<0.001 and multivariable-adjusted HR 1.07 95%CI [1.02-1.12], P=0.005). 256 
Similarly, for each 1 point increase in AAC24 score there was an 8-9% increase in age and 257 
multivariable-adjusted risk of all-cause mortality (age-adjusted HR 1.09 95%CI [1.06-1.13], 258 
P<0.001 and multivariable-adjusted HR 1.08 95%CI [1.04-1.13], P<0.001). In the 259 
multivariable-adjusted restricted cubic spline regression model there was an increasing 260 
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gradient of estimated CV event and all-cause mortality risk with increasing AAC24 scores 261 
(Figure 4 a & b). 262 
 263 
Presence of AAC and CV events and all-cause mortality 264 
In recipients with no AAC, the rate of CV events was 6.2, 95%CI (3.6-10.7) per 1000 person 265 
years and deaths was 9.0, 95%CI (5.7-14.1) per 1000 person years. By comparison, in 266 
recipients with AAC, the rates of CV events and deaths were 21.3, 95%CI (15.1-29.9) and 267 
24.7, 95%CI (18.1-33.6) respectively. In univariate analysis recipients with any AAC had a 268 
HR of 3.50 95%CI (1.82-6.58) for CV events and 2.80 95%CI (1.62-4.83) for all-cause 269 
mortality (both P<0.001). In age and multivariable-adjusted analyses the presence of AAC 270 
was associated with at least twice the relative hazard of having a cardiovascular event or 271 
dying from any cause (Table 2).  272 
 273 
Severity of AAC and cardiovascular events and all-cause mortality  274 
Of the 623 patients, 348 (55.9%) had no AAC, 162 (26.0%) had moderate AAC (score 1-7) 275 
and 113 (18.1%) had high AAC (score 8-24). Using these cut points, Kaplan Meier survival 276 
estimates for CV events and all-cause mortality by the severity of AAC are presented in 277 
Supplementary Figure 1. The rate of CV events per 1000 person years was 6.2, 95%CI (3.6-278 
10.7) in recipients with no AAC, 14.3, 95%CI (8.5-24.1) in recipients with moderate AAC 279 
and 33.2, 95%CI (21.2-52.1) in recipients with high AAC. The rate of all-cause mortality per 280 
1000 person years was 9.0, 95%CI (5.7-14.1) in recipients with no AAC, 11.9, 95%CI (6.7-281 
20.9) in recipients with moderate AAC and 45.8, 95%CI (31.7-66.4) in recipients with high 282 
AAC. In unadjusted Cox proportional hazards analysis, transplant recipients with high AAC 283 
had 5-6 times higher relative hazards of CV events and all-cause mortality (5.90 95%CI [2.9, 284 
12.02] and 5.39 95%CI [3.00-9.68], both P<0.001). Recipients with moderate AAC had 285 
higher relative hazards for CV events than those with no AAC HR 2.22 95%CI (1.04-4.73), 286 
P=0.039.  In age-adjusted models, transplant recipients with high AAC had at least 3 times 287 
the relative hazards for CV events and all-cause mortality compared to recipients with no 288 
AAC. This remained significant in multivariable-adjusted models (Table 2).  289 
 290 
Graft loss 291 
Overall 80 recipients lost any graft, comprising 42 [10.2%] of kidney recipients and 38 292 
[17.8%] of SPK recipients, (P=0.007). Kidney graft loss occurred in 60 transplant recipients 293 
(kidney only 42 [10.2%] and SPK 18 [8.5%], P=0.567), while 20 SPK recipients lost their 294 
10 
 
pancreas graft and 4 lost both the pancreas and kidney. There was no significant increase in 295 
age-adjusted risk for death-censored a) kidney, b) pancreas, or c) any graft loss graft loss per 296 
1 point increase in AAC24 score (age-adjusted HR 1.04 95%CI [0.99-1.09], P=0.136, HR 297 
1.03 95%CI [0.94-1.12], P=0.552 and HR 1.04 95%CI [1.00-1.09], P=0.069, respectively). 298 
This was similar in multivariable-adjusted analyses. For transplant recipients with detectable 299 
versus no detectable AAC, there was no difference in graft loss in unadjusted (data not 300 
shown) age-adjusted or multivariable-adjusted analyses (Supplementary Table 1). In 301 
unadjusted analyses recipients with the most severe AAC (AAC24 ≥8) did not have increased 302 
relative hazards for graft loss compared to those with no AAC (HR 1.30 95%CI [0.75-2.28], 303 
P=0.351). However in age and smoking history-adjusted analyses, recipients with severe 304 
AAC had 1.9 times higher relative hazard for graft loss compared to those with no AAC 305 
(Supplementary Table 1).  306 
 307 
Further analyses 308 
When death from any non-CV cause was considered in competing risk analyses for CVD 309 
outcomes, findings were similar to the primary analyses (Supplementary Table 2). 310 
Similarly, when death from any cause was included in competing risks analyse for kidney 311 
graft loss or any graft loss, there was no alteration of the overall results (Supplementary 312 
Table 2). Finally, including death with a functioning kidney graft or death with any 313 
functioning graft in analyses, strengthened the observed association between AAC and 314 
mortality (severe AAC vs no AAC, aHR 4.42 [2.04-9.62], p<0.001). 315 
 316 
317 
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Discussion 318 
This prospective study highlights several important and novel findings. Firstly, for 319 
patients undergoing kidney and SPK transplantation, the presence and the severity of AAC 320 
was associated with CV events and mortality, with no significant differences between kidney 321 
and SPK transplant recipients over time. Secondly, we report a continuous, positive 322 
relationship of AAC scores to cardiovascular risk and mortality. Thirdly, we report for the 323 
first time that severe AAC is associated with kidney and/or pancreas graft loss. High AAC 324 
scores may be surrogates for reduced graft perfusion or a greater propensity for vascular 325 
damage.  326 
 Conventional risk factors that are markers of pathological processes leading to blood 327 
vessel damage consistently underestimate CV risk [23] or do not improve net reclassification 328 
compared to age, gender and eGFR in kidney transplant recipients[24]. Vascular calcification 329 
on the other hand is a structural measure of the amount of damage to the blood vessel and has 330 
been shown to be strongly associated with increased risk of CV events[6,17]. The increased 331 
risks in this study were particularly evident in those with AAC24 scores ≥8, similar to some 332 
earlier reports of transplant recipients. However, unlike those studies, we excluded people 333 
with prior transplantation or a history of CV disease, both of which could influence the 334 
accuracy of AAC to predict CV outcomes.  335 
 In a retrospective study of 253 kidney transplant recipients [6], the authors reported a 336 
relative HR of 1.09 per 1 point increase in AAC24 score with a univariate HR of 3.1 in 337 
kidney transplant recipients with high AAC. In a retrospective study of 119 older kidney 338 
transplant recipients [19], AAC24 scores >2 were associated with a relative risk of 3.8 for CV 339 
events, compared to those with AAC24 scores of 0-2. A study of 701 kidney transplant 340 
recipients using DXA images to assess AAC[17], found that after adjusting for CV risk 341 
factors, transplant recipients with higher AAC had an increased relative hazard of 2.78 for 342 
cardiovascular events, compared to recipients with no AAC. Taken together, these data and 343 
the current study support the concept that transplant recipients with AAC, and particularly 344 
those with high AAC scores, are at high risk for future CV events.  345 
The Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD guidelines suggest 346 
that a lateral abdominal radiograph can be used to detect the presence or absence of vascular 347 
calcification in patients with CKD G3a–G5D, and that patients with known vascular 348 
calcification are at highest CV risk[25]. However, neither the KDIGO CKD-MBD nor 349 
transplantation guidelines[26] comment on the value of AAC screening to identify 350 
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individuals at high CV risk at the time of transplantation. While lateral spine radiographs are 351 
relatively low radiation, equivalent to approximately 20 days of natural background radiation 352 
[27], lateral DXA may also be used to evaluate AAC, with a much lower radiation 353 
exposure[24]. 354 
Because capturing these images is safe, simple and inexpensive, this study supports 355 
AAC screening in patients undergoing kidney or SPK transplantation. Once identified, 356 
patients at greatest risk could be targeted for intensive modification of ‘traditional’ CV risk 357 
factors, which may have greater impact on outcomes once the calcifying ESKD milieu 358 
improves. In addition, these patients could be targeted to assess modifications in the 359 
prescription of calcium and activated vitamin D, the addition of supplemental vitamin K or 360 
magnesium, and introduction of drugs with potential to delay progressive vascular 361 
calcification. Patients with high AAC scores might also be considered for more intensive 362 
monitoring of graft function  363 
For patients with type 1 diabetes, successful SPK transplantation removes the need for 364 
insulin injections, restores normal glycaemic control and reverses systemic microvascular 365 
structural abnormalities [28]. SPK recipients have slower progression of coronary 366 
atherosclerosis (minimum obstruction diameter loss 0.037 mm/year vs 0.061 mm/year). 367 
When patients with type 1 diabetes undergoing SPK or kidney-only transplantation are 368 
compared, SPK recipient have greater regression of atherosclerosis (38% vs. 0%) [29]. 369 
Compared to kidney-only transplantation, these SPK recipients have improved long-term 370 
survival, predominantly from 5 years after transplantation [30]. However, we observed 371 
similar associations between AAC scores and incident CV events and mortality in both 372 
kidney-only and SPK recipients, suggesting that pre-transplant vascular damage is a major 373 
driver of later CV and mortality risk. Therefore strategies to monitor and intervene early to 374 
reduce pre-transplant AAC are warranted. Furthermore, our findings support the concept that 375 
AAC is a stable marker of long-term CV and all-cause mortality risk in bother groups of 376 
transplant recipients. 377 
 This study has some limitations and a number of strengths. Firstly, AAC prevalence in 378 
this study is likely to underestimate that of older dialysis patients, patients with type 2 379 
diabetes mellitus or prevalent CV disease, who are often excluded from transplantation. 380 
Therefore our findings may underestimate the association of AAC, CV events and mortality 381 
in the general dialysis population and for transplant recipients with pre-existing CV disease. 382 
As indicated in the methods, some transplanted patients were not included in these analyses, 383 
which may have introduced selection bias. Also, the relatively young age of these kidney and 384 
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SPK recipients resulted in a low rate of CV events and deaths. Furthermore, we did not 385 
collect or adjust for pre-transplant CV risk factors such as low density lipoprotein cholesterol 386 
or CV medication use such as statins, which may have attenuated the relationship between 387 
AAC and CV events. Due to patient numbers, we undertook minimally adjusted models for 388 
associations of AAC to graft survival that did not include induction therapy or 389 
immunosuppressive medications and pre-transplant laboratory data. Including these may have 390 
attenuated the observed associations. Finally, our findings may not be generalisable to studies 391 
using other imaging modalities or scoring systems.  392 
Study strengths include it being the largest and first prospective study using standard 393 
X-ray to assess patient and graft outcomes, and the first to include a large cohort of SPK 394 
recipients. Secondly, we describe the continuous, positive relationship between AAC scores 395 
and cardiovascular event and all-cause mortality risk. Additional strengths include 396 
comprehensive, accurate pre and post-transplant data collection in the clinic and in real time 397 
by the ANZDATA Registry. Finally, this is the first study to perform competing risks 398 
analysis or death with a functioning graft analyses. 399 
 In conclusion, in a large cohort of kidney and SPK transplant recipients, AAC on 400 
lateral spine radiographs identified transplant recipients at high risk of cardiovascular events 401 
and all-cause mortality. For secondary outcomes, recipients with severe AAC at 402 
transplantation also had significantly poorer graft outcomes compared to those with no AAC. 403 
In patients with high AAC scores detected at the time of kidney or SPK transplantation, 404 
future studies should evaluate whether, compared to usual care, intensive interventions aimed 405 
to reduce CV risk and progressive vascular calcification might impact incident CV events and 406 
mortality. 407 
 408 
 409 
 410 
 411 
 412 
 413 
 414 
 415 
 416 
 417 
 418 
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Table 1. Baseline characteristics of the study population stratified by abdominal aortic calcification (AAC) scores.  
 Whole cohort* 
(n=623) 
Kidney only 
 (n=410) 
Simultaneous pancreas-
kidney (n=213) 
Age, years, mean ± SD 44.1 ± 11.9 47.0 ± 12.8 38.5 ± 7.0 
Gender, (%)    
    Female (%) 257 (41.3) 161 (39.3) 96 (45.1) 
    Male, (%) 366 (58.7) 249 (60.7) 117 (54.9) 
Body mass index, kg/m2, mean ± SD† 25.9 ± 4.4 26.6 ± 4.6 24.5 ± 3.5 
Dialysis type, number (%)**    
    Haemodialysis (%) 329 (53.8) 230 (57.1) 99 (47.6) 
    Peritoneal dialysis (%) 185 (30.3) 119 (29.5) 66 (31.7) 
    Pre-emptive (%) 97 (15.9) 54 (13.4) 43 (20.7) 
Dialysis vintage, months, median [IQR] 20.0 [6.0-48.0] 29.0 [9.0-60.5] 12.0 [3.0-30.0] 
Ethnicity, number (%)    
    Asian (%) 80 (12.8) 77 (18.8) 3 (1.4) 
    Caucasian (%) 496 (79.6) 297 (72.4) 199 (93.4) 
    Other (%) 47 (7.5) 36 (8.8) 11 (5.2) 
Smoking history, number (%)‡    
    Never (%) 389 (63.1) 261 (64.1) 128 (61.2) 
    Previous (%) 180 (29.2) 114 (28.0) 66 (31.6) 
    Current (%)                           47 (7.6) 32 (7.9) 15 (7.2) 
Diabetes, number (%)    
   Never, (%) 352 (56.5) 352 (85.9) 0 (0) 
   Type I (%) 225 (36.1) 12 (2.9) 213 (100)  
   Type II (%) 46 (7.4) 46 (11.2) 0 (0) 
Calcium, (mmol/L), median [IQR]   2.30 [2.19-2.43] 2.30 [2.19-2.44] 2.31 [2.21-2.39] 
Phosphorus, (mmol/L), median [IQR] 1.60 [1.28-1.95] 1.55 [1.24-1.89] 1.69 [1.37-2.02] 
Parathyroid hormone, (pmol/L), median [IQR] 34.2 [15.5-63.8] 35.8 [14.5-70.7] 32.7 [18.0-51.7] 
Alkaline phosphatase, (U/L), median [IQR] 102 [75-145] 92 [70-138] 120 [93-154] 
Donor factors    
   Donor age, years, mean ± SD 41.3 ± 16.0 48.5 ± 13.7 27.3 ± 9.4 
   Donor ischemia time, hours, mean ± SD  8.4 ± 4.7 7.5 ± 5.1 10.4 ± 2.8 
Donor type    
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    Deceased donor,  421 (67.6) 208 (50.7) 213 (100) 
    Living donor, 202 (32.4) 202 (49.3) 0 (0) 
HLA-mismatches 3.6 ± 1.8 3.2 ± 1.8 4.3 ± 1.2 
Data expressed as mean ± SD, median [IQR=interquartile range] or number and (%). * For patients undergoing simultaneous pancreas-kidney 
transplants, the cause of ESKD was type 1 diabetes mellitus. For patients undergoing kidney only transplants, the most common causes of ESKD 
were glomerulonephritis, polycystic kidney disease and vesicoureteric reflux. 
†Data available for 488 recipients. **Data available for 611 recipients. ‡Data available for 616 recipients.  
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Table 2. Cox regression for CV events or all-cause mortality stratified by the presence and severity of abdominal aortic calcification (AAC). 
 Number (%)  Age-adjusted  
HR (95% CI) 
P 
value 
Multivariable-adjusted 
HR (95% CI)* 
P 
value 
Presence of AAC (any)      
Cardiovascular event 46     
     No AAC (AAC24 score 0) 13/348 (3.7) 1 (reference)  1 (reference)  
     Any AAC (AAC24 score 1-24) 33/275 (12.0) 2.53 (1.29-4.96) 0.007 2.23 (1.11-4.50) 0.024 
All deaths 59     
     No AAC (AAC24 score 0) 19/348 (5.5) 1 (reference)  1 (reference)  
     Any AAC (AAC24 score 1-24) 40/275 (14.5) 2.07 (1.16-3.68) 0.014 1.81 (0.99-3.31) 0.053 
Severity of AAC       
Cardiovascular event 46     
     No AAC (AAC24 score 0) 13/348 (3.7) 1 (reference)  1 (reference)  
     Moderate AAC (AAC24 score 1-7) 14/162 (8.6) 1.79 (0.83-3.87) 0.141 1.71 (0.78-3.75) 0.183 
     High AAC (AAC24 score ≥8) 19/113 (16.8) 4.04 (1.89-8.67) <0.001 3.51 (1.54-8.00) 0.003 
     P for trend†  <0.001  <0.001  
Any death 59     
     No AAC (AAC24 score 0) 19/348 (5.5) 1 (reference)  1 (reference)  
     Moderate AAC (AAC24 score 1-7) 12/162 (7.4) 1.09 (0.52-2.28) 0.815 1.05 (0.50-2.22) 0.902 
     High AAC (AAC24 score ≥8) 28/113 (24.8) 3.88 (2.05-7.34) <0.001 3.38 (1.71-6.70) <0.001 
     P for trend†  <0.001  <0.001  
Abbreviations: AAC; Abdominal aortic calcification, CV; Cardiovascular event, HR; hazard ratio. *Cox proportional hazards regression 
analyses were adjusted for age or age, gender, smoking history, type of kidney transplant (kidney only or SPK), dialysis vintage and diabetes. 
Values in bold p<0.05 compared to recipient with no AAC. †P values are a trend test using the median values of each AAC category in the 
Cox proportional hazards models. 
 
18 
 
Figure legend 
 
Figure 1. Overview of study including; A) Flowchart of the study participants, B) Example 
of lateral spine radiograph showing predominantly linear AAC typical of chronic kidney 
disease.   
 
Figure 2. Kaplan Meier Survival plots (n=623) by the presence or absence of AAC for a) 
cardiovascular  (CV) events (n=46) and b) deaths (n=59). Vertical lines indicate censored 
individuals. 
 
Figure 3. Kaplan Meier Survival plots by presence of AAC for cardiovascular (CV) events 
A) kidney only (n=410) and B) simultaneous pancreas-kidney transplant (n=213) and all 
cause mortality C) kidney only (n=410) and D) simultaneous pancreas-kidney transplant 
(n=213). Vertical lines indicate censored individuals. 
 
Figure 4. Multivariable-adjusted restricted cubic spline regression for the association 
between AAC24 scores and a) cardiovascular events and b) all-cause mortality. Adjusted for 
age, gender, smoking history, type of kidney transplant (kidney only or SPK), dialysis 
vintage and diabetes. 
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